Primary Aldosteronism Market is Expected to Expand at a promising CAGR of 8.4% During Forecast 2018-2023
Market Highlights: Increasing prevalence of primary aldosteronism, growing geriatric population, rising number of obese individuals in the developing as well as the developed regions and increasing consumption of alcohol are estimated to drive the market growth during the forecast period. Moreover, rising per capita healthcare expenditure boosts the growth of primary aldosteronism. However, lack of awareness and risks of excessive bleeding, infection, anesthesia reaction by the corrective surgeries will restrain the market growth during the projected period. Key Players: · Pfizer Inc · Sun Pharmaceutical Industries Ltd · Bristol Laboratories Ltd · CMP Pharm · Koninklijke Philips N.V · ...